Search

e13107 Background: Programmed death ligand 1 (PD-L1) expressions is a known predictor for anti-PD1 therapy outcomes. This study is the first study that describe the status of PD-L1 status on Vietnamese non-small cell lung cancers (NSLCs) patients. Methods: Patients who were diagnosed with advanced NSCLCs and PD-L1 testing from 14 Dec 2017 to 14 Dec 2018 at The Pathology Center, Bach Mai Hospital, Hanoi, Vietnam. Study team collected data of age, gender, histopathological types, biopsy sites and PD-L1 expressions. Qualified pathologists interpret levels of PD-L1 via immunohistochemical (IHC) assays Ventana PD-L1 (SP263) with archive formalin-fixed, paraffin-embedded (FFPE) NSCLCs tissues (primary lung tumor or metastases) on VENTANA BenchMark XT. Results: In total 166 patients, the majority were male (73.49%) with male/female ratio is 2.77. Age range from 29 to 85 with median age was 61 years old. The most common histopathological type was adenocarcinoma (n = 143, 86.14%). Other patients including 19 squamous cell carcinoma (11.45%) and 3 patients with “not otherwise specified” (NOS) tissues (2.41%). Overall 127/166 (76.51%) specimens were taken from lung tumors while 39 (23.49%) samples were from lymph node (10), pleura (20), liver (2), pericardia (2), brain (3) and bone (2). Rates of high expression (≥50%), expression (≥1% and ≤49%) and no expression (

BACKGROUND/AIM Patients with gynecological malignancies account for 2% of patients with cerebral metastases. Many patients receive whole-brain irradiation (WBI) alone. Local therapies (resection, stereotactic radiosurgery (SRS)) are becoming more popular. This study compared intracerebral control after local therapy to WBI alone in patients with gynecological malignancies. PATIENTS AND METHODS Of 56 patients, 45 received WBI alone, 6 SRS alone and 5 resection plus WBI. Treatment type, age, performance score, cancer site, number of cerebral lesions, metastases outside the brain, recursive partitioning analysis (RPA) class and period from gynecological cancer diagnosis to brain metastasis treatment were evaluated. RESULTS On univariate analyses, local therapy (p=0.003), single cerebral lesion (p

This study aimed to determine factors allowing the prediction of extracranial metastases in patients presenting with brain metastases at the first diagnosis of cancer.Data from 659 patients with brain metastases upon first diagnosis of cancer were retrospectively analyzed. The parameters age, gender, Karnofsky performance score (KPS), primary tumor type and number of brain metastases were compared between 359 patients with extracranial metastases and 300 patients without extracranial metastases. Additional analyses were performed for patients with the most unfavorable and those with the most favorable characteristics.The comparison of patients with versus without extracranial metastases revealed significant differences between the groups in terms of KPS (p 0.001) and number of brain metastases (p 0.001). Of the study patients, 113 had both most unfavorable characteristics, i.e. KPS ≤ 50 and ≥ 4 brain metastases. The sensitivity for identifying patients with extracranial metastases was 82 %; specificity was 51 %. A total of 50 patients had KPS ≥ 90 and only one brain metastasis. The sensitivity for identifying patients without extracranial metastases was 86 %; specificity was 58 %.The combination of KPS and the number of brain metastases can help to predict the presence or absence of extracranial metastases.

In oncology, elderly people are a separate group of patients requiring special consideration. This applies to the treatment of cerebral metastases as well. The present study focused on elderly patients receiving stereotactic radiosurgery (SRS) for few cerebral lesions.In 95 patients aged ≥65 years, two SRS doses, 16-18 Gy (n=44) and 20 Gy (n=51), were compared regarding outcomes of SRS.The overall intracerebral control rates at 12 months were 30% after 16-18 Gy and 45% after 20 Gy (p=0.53). Twelve-month rates of freedom from new intracerebral lesions were 41% and 52%, respectively (p=0.63). Twelve-month local control rates of the irradiated lesions were 55% and 81%, respectively (p=0.069). Overall survival rates at 12 months were 29% and 31%, respectively (p=0.67).SRS with 16-18 Gy was not significantly inferior to SRS with 20 Gy in elderly patients with few cerebral metastases.

Patients with cerebral metastases from head and neck cancer are not common. This study aimed to create an instrument for estimating survival in this particular group of patients.Survival was significantly influenced by Eastern Cooperative Oncology Group (ECOG) performance score, number of cerebral lesions and extracranial metastatic disease. These characteristics were included in our score.Scoring was based on 6-month survival data: ECOG 0-1=1 point, ECOG 2-3=0 points, 1-3 cerebral lesions=1 point, ≥4 cerebral lesions=0 points, lack of extracranial metastases=1 point, and presence of extracranial metastases=0 points. Addition of these points for each patient resulted in 0-3 points. Three groups were built comprising 0-1, 2 and 3 points. Six-month survival rates for these groups were 0%, 50% and 100%, respectively.This new instrument guides physicians in choosing optimal irradiation programs for patients with cerebral metastases from head-and-neck cancer.

To generate an overall survival score for patients with kidney cancer who underwent radiosurgery for brain metastases.Thirty-six patients who received radiosurgery alone for 1-3 brain metastases from kidney cancer were included. On multivariate analysis of a preceding study of such patients, Karnofsky performance score (KPS) and extracranial spread were significantly associated with overall survival and formed the basis for this score. For each patient, the prognostic score was derived from adding the points of KPS and extracranial spread resulting in a score of 9, 12, 15 or 18 points.Six-month overall survival rates were 13% for patients with 9 points, 80% for those with 12 points, 79% for those with 15 points and 100% for those with 18 points, respectively. Three groups of patients were defined with scores of 9, 12-15 and 18 points. Six-month overall survival rates were 13%, 79% and 100%, respectively (p=0.004).This new score facilitates personalized treatment decisions for patients with kidney cancer with very few brain metastases.

Renal cell carcinoma (RCC) is a relatively radioresistant tumor and may require for higher radiation doses than other tumor types.Nineteen patients treated with 20 Gy of stereotactic radiosurgery (SRS) alone for one to three cerebral metastases were compared to nine patients treated with 16-18 Gy.SRS with 20 Gy led to significantly better local control than did 16-18 Gy (81% vs. 50% at 12 months; p0.001). Results were also significant on multivariate analysis (risk ratio: 6.30; p=0.033). SRS dose did not associate with freedom from new cerebral metastases (75% vs. 62% at 12 months; p=0.42) or survival (16% vs. 56% at 12 months; p=0.46). On multivariate analyses, better survival was associated with higher Karnofsky performance score (p0.001) and absence of extracranial metastatic disease (p=0.006).In patients treated with SRS alone, local control of cerebral metastases from RCC was better after 20 Gy than after 16-18 Gy.

Two dose groups of patients treated with stereotactic radiosurgery (SRS) alone for 1-3 brain metastases from non-small cell lung cancer (NSCLC) were compared for outcomes.Based on the SRS dose administered to the margins of the brain lesions, 46 patients were assigned to groups treated with 15-18 Gy (n=13) or with 20 Gy (n=33). Seven additional factors were investigated: age (≤ 58 vs. ≥ 59 years), gender, Karnofsky performance score (KPS 70-80 vs. 90-100), number of brain metastases (1 vs. 2-3), histology (adenocarcinoma vs. other) extracerebral metastases and interval from NSCLC diagnosis to SRS (≤ 6 vs.6 months).Local control rates for 15-18-Gy and 20-Gy groups were 75% and 92% at one year (p=0.043). SRS dose was significant on multivariate analysis (p=0.030). SRS dose was not associated with freedom from new brain metastases (p=0.24) or survival (p=0.37).SRS with 20 Gy resulted in better control of the irradiated metastases than 15-18 Gy did.

Elderly patients represent an important subgroup of patients with brain metastases. A survival score has been developed specifically for these patients.A total of 544 elderly patients (aged ≥65 years) receiving whole-brain radiotherapy alone were divided into a test (n=272) and a validation group (n=272). In the multivariate analysis of the test group, survival was significantly associated with gender, performance status, and number of organs involved by extracranial metastases. These factors were included in the score. Total scores representing the sum of the three factor scores were 3-13 points. Four prognostic groups were formed.The 6-month survival rates were 2% for those with 3-6 points, 17% for those with 7-9 points, 56% for those with 10-12 points and 90% for those with 13 points in the test group (p0.001), and 4%, 21%, 50% and 86%, respectively, in the validation group (p0.001).This score is reproducible and helps estimate the survival prognosis of elderly patients with brain metastasis.

Three doses were compared for local control of irradiated metastases, freedom from new brain metastases, and survival in patients receiving stereotactic radiosurgery (SRS) alone for one to three newly diagnosed brain metastases.In all, 134 patients were assigned to three groups according to the SRS dose given to the margins of the lesions: 13-16 Gy (n = 33), 18 Gy (n = 18), and 20 Gy (n = 83). Additional potential prognostic factors were evaluated: age (≤ 60 vs.60 years), gender, Karnofsky Performance Scale score (70-80 vs. 90-100), tumor type (non-small-cell lung cancer vs. melanoma vs. others), number of brain metastases (1 vs. 2-3), lesion size (15 vs. ≥ 15 mm), extracranial metastases (no vs. yes), RPA class (1 vs. 2), and interval of cancer diagnosis to SRS (≤ 24 vs.24 months).For 13-16 Gy, 18 Gy, and 20 Gy, the 1-year local control rates were 31, 65, and 79%, respectively (p0.001). The SRS dose maintained significance on multivariate analysis (risk ratio: 2.25; 95% confidence interval: 1.56-3.29; p0.001). On intergroup comparisons of local control, 20 Gy was superior to 13-16 Gy (p0.001) but not to 18 Gy (p = 0.12); 18 Gy showed a strong trend toward better local control when compared with 13-16 Gy (p = 0.059). Freedom from new brain metastases (p = 0.57) and survival (p = 0.15) were not associated with SRS dose in the univariate analysis.SRS doses of 18 Gy and 20 Gy resulted in better local control than 13-16 Gy. However, 20 Gy and 18 Gy must be compared again in a larger cohort of patients. Freedom from new brain metastases and survival were not associated with SRS dose.

This study was performed to investigate the potential impact of the number of involved extracranial organs on survival in patients with brain metastasis from breast cancer.The data of 196 patients treated with whole-brain radiotherapy (WBRT) alone for brain metastases from breast cancer were retrospectively analyzed. Six potential prognostic factors were evaluated for associations with survival. These factors included WBRT regimen, age, Karnofsky performance score (KPS), number of brain metastases, interval from breast cancer diagnosis to WBRT, and the number of involved extracranial organs.The 6-month survival rates of patients with involvement of 0, 1, 2, 3 and ≥4 extracranial organs were 59%, 49%, 26%, 26% and 13%, respectively, and the 12-month survival rates were 45%, 36%, 17%, 17% and 13%, respectively (p0.001). On multivariate analysis, the number of involved extracranial organs (risk ratio 1.17; 95%-confidence interval 1.02-1.35; p=0.028) maintained significance, as did KPS (p0.001), but not age (p=0.27).The number of involved extracranial organs is an independent prognostic factor of survival in patients with brain metastasis from breast cancer.

This study investigated the potential prognostic value of the number of involved extracranial organs in patients with brain metastasis from non-small cell lung cancer (NSCLC). A total of 472 patients who received whole-brain radiotherapy (WBRT) alone with 5 × 4 Gy or 10 × 3 Gy for brain metastasis from NSCLC were included in this retrospective study. In addition to the number of involved extracranial organs, 6 further potential prognostic factors were investigated including WBRT regimen, age, gender, Karnofsky Performance Score (KPS), number of brain metastases, and the interval from cancer diagnosis to WBRT. Subgroup analyses were performed for patients with metastatic involvement of one (lung vs. bone vs. other metastasis) and two (lung + bone vs. lung + lymph nodes vs. other combinations) extracranial organs. The survival rates at 6 months of the patients with involvement of 0, 1, 2, 3, and ≥ 4 extracranial organs were 52, 27, 17, 4, and 14 %, respectively (p

BACKGROUND AND PURPOSE This study was performed to evaluate the prognostic role for survival of the number and the type of involved extracranial organs in patients with brain metastasis. MATERIAL AND METHODS The data of 1146 patients who received whole-brain radiotherapy (WBRT) alone for brain metastasis have been retrospectively analyzed. In addition to the number of involved extra cranial organs, seven potential prognostic factors were investigated including WBRT regimen, age, gender, Karnofsky Performance Score (KPS), primary tumor type, number of brain metastases, and the interval from cancer diagnosis to WBRT. Additionally, subgroup analyses were performed for patients with involvement of one (lung vs. bone vs. liver vs. other metastasis) and two (lung + lymph nodes vs. lung + bone vs. lung + liver vs. liver + bone vs. other combinations) extracranial organs. RESULTS The 6-month survival rates for the involvement of 0, 1, 2, 3, and ≥4 extracranial organs were 51, 30, 16, 13, and 10%, respectively (p

Personalized cancer treatment considers the patient's survival prognosis. Therefore, it is important to be able to estimate the patient's survival time, particularly in a palliative situation such as brain metastasis. This study aimed to create and validate a survival score for patients with brain metastasis from breast cancer, which is the second most common primary tumor in these patients.Data of 230 patients treated with whole-brain radiotherapy (WBRT) alone for brain metastasis from breast cancer were retrospectively analyzed. Patients were assigned to a test (n = 115) or a validation group (n = 115). According to the results of the multivariate analysis of the test group, Karnofsky Performance Score and extracranial metastases were included in the scoring system. The score for each factor was obtained from the 6-month survival rate (in %) divided by 10. Total scores represented the sum of these scores and were 4, 7, 9, or 12 points. Three prognostic groups were formed.The 6-month survival rates in the test group were 10 % for 4-7 points, 55 % for 9 points, and 78 % for 15 points (p 0.001). In the validation group the corresponding 6-month survival rates were 11, 54, and 75 %, respectively (p 0.001). The comparisons between the prognostic groups of the test and the validation group did not show significant differences.This simple survival score appears valid and reproducible. It can be used to estimate the survival time of patients with brain metastasis from breast cancer receiving WBRT alone.